GlobeNewswire: IMV Inc. Contains the last 10 of 72 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:08:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/01/1745386/0/fr/IMV-Inc-annonce-le-prix-de-son-placement-public.html?f=22&fvtc=4&fvtv=34385IMV Inc. annonce le prix de son placement public2019-03-01T16:05:07Z<![CDATA[DARTMOUTH, Nouvelle-Écosse, 01 mars 2019 (GLOBE NEWSWIRE) -- IMV Inc. (« IMV » ou la « société ») (NASDAQ : IMV; TSX : IMV), société de recherche clinique en immuno‑oncologie, annonce aujourd’hui le prix de son placement public par voie de prise ferme déjà annoncé (le « placement ») de 4 900 000 actions ordinaires à un prix d’offre de 5,45 $ CA l’action ordinaire, pour un produit brut total revenant à la société d’environ 26,705,000 de dollars CA, avant déduction des décotes et commissions de prise ferme et des frais estimatifs du placement. La société a en outre accordé aux preneurs fermes du placement une option de 30 jours leur permettant de souscrire jusqu’à 735 000 actions ordinaires additionnelles aux mêmes conditions. Toutes les actions sont offertes par la société.]]>https://www.globenewswire.com/news-release/2019/03/01/1745366/0/en/IMV-Inc-Announces-Pricing-of-Public-Offering.html?f=22&fvtc=4&fvtv=34385IMV Inc. Announces Pricing of Public Offering2019-03-01T15:02:37Z<![CDATA[DARTHMOUTH, Nova Scotia, March 01, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 4,900,000 common shares at a price to the public of Cdn$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately Cdn$26,705,000 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Corporation has granted the underwriters of the Offering a 30-day option to purchase up to an additional 735,000 common shares on the same terms and conditions. All of the shares are being offered by the Corporation.]]>https://www.globenewswire.com/news-release/2019/02/28/1744895/0/fr/IMV-Inc-d%C3%A9pose-un-suppl%C3%A9ment-de-prospectus-provisoire-dans-le-cadre-d-un-projet-d-appel-public-%C3%A0-l-%C3%A9pargne-visant-des-actions-ordinaires.html?f=22&fvtc=4&fvtv=34385IMV Inc. dépose un supplément de prospectus provisoire dans le cadre d’un projet d’appel public à l’épargne visant des actions ordinaires2019-02-28T21:53:29Z<![CDATA[DARTHMOUTH, Nouvelle-Écosse, 28 févr. 2019 (GLOBE NEWSWIRE) -- IMV Inc. (« IMV » ou la « société ») (NASDAQ : IMV; TSX : IMV), société de recherche clinique en immuno‑oncologie, dépose aujourd’hui un supplément de prospectus provisoire (le « supplément ») à son prospectus préalable de base simplifié daté du 5 juin 2018 (le « prospectus préalable de base ») dans le cadre d’un projet d’appel public à l’épargne visant ses actions ordinaires (le « placement »). Le supplément a été déposé auprès des autorités en valeurs mobilières des provinces de la Colombie‑Britannique, d’Alberta, de la Saskatchewan, du Manitoba, d’Ontario, de Québec, de la Nouvelle‑Écosse et de Terre‑Neuve‑et‑Labrador. Le supplément a également été déposé auprès de la Securities and Exchange Commission des États‑Unis (la « SEC ») dans le cadre d’une déclaration d’inscription sur Formulaire F-10, en sa version modifiée (la « déclaration d’inscription »), que la SEC a déclarée valide le 6 juin 2018, selon le régime d’information multinational établi entre le Canada et les États‑Unis.]]>https://www.globenewswire.com/news-release/2019/02/28/1744894/0/en/IMV-Inc-Files-Preliminary-Prospectus-Supplement-for-Proposed-Public-Offering-of-Common-Shares.html?f=22&fvtc=4&fvtv=34385IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares2019-02-28T21:51:35Z<![CDATA[DARTMOUTH, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated June 5, 2018 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Québec, Nova Scotia and Newfoundland and Labrador. The Supplement was also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration statement on Form F-10, as amended (the “Registration Statement”), which was declared effective by the SEC on June 6, 2018, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.]]>https://www.globenewswire.com/news-release/2019/01/29/1706703/0/en/IMV-Announces-Clinical-Update-for-DPX-Survivac-Program-in-Ovarian-Cancer-Following-Positive-Feedback-from-U-S-FDA.html?f=22&fvtc=4&fvtv=34385IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA2019-01-29T12:05:00Z<![CDATA[DARTMOUTH, Nova Scotia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced updates on its clinical program for its lead investigational treatment, DPX-Survivac, as a potential monotherapy in advanced recurrent ovarian cancer. In December 2018, IMV met with the U.S. Food and Drug Administration (FDA) in a Type B meeting to discuss the results-to-date of its DECIDE1 clinical trial and ongoing development plan, as well as to obtain agency guidance on a potential accelerated regulatory pathway for DPX-Survivac as a T cell immunotherapy for the treatment of advanced ovarian cancer in patients with progressing disease.]]>https://www.globenewswire.com/news-release/2019/01/28/1706455/0/en/IMV-to-Present-at-2019-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=34385IMV to Present at 2019 BIO CEO & Investor Conference2019-01-28T21:35:00Z<![CDATA[DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and Investor Conference in New York City, NY. This event will take place February 11-12, 2019, at the New York Marriott Marquis.]]>https://www.globenewswire.com/news-release/2019/01/17/1701188/0/en/First-Patient-Dosed-in-Phase-1-Clinical-Trial-Evaluating-Neoepitopes-Formulated-in-IMV-s-DPX-Delivery-Platform-in-Ovarian-Cancer-Patients.html?f=22&fvtc=4&fvtv=34385First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients2019-01-17T12:05:00Z<![CDATA[DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the Company’s proprietary DPX delivery platform in patients with ovarian cancer. The study is part of the Company’s DPX-NEO program, which is an ongoing collaboration between UConn Health and IMV to develop neoepitope-based anti-cancer therapies.]]>https://www.globenewswire.com/news-release/2018/12/13/1666399/0/en/IMV-Inc-Presents-Updated-Positive-Data-From-Phase-1b-2-Combination-Clinical-Trial-in-Advanced-Ovarian-Cancer-at-2018-ESMO-Immuno-Oncology-Congress.html?f=22&fvtc=4&fvtv=34385IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress2018-12-13T09:05:00Z<![CDATA[73% of tumor regressions and 80% of clinical responses were observed in a subpopulation defined by a clinical biomarker based on Baseline Tumor Burden]]>https://www.globenewswire.com/news-release/2018/12/10/1664264/0/en/IMV-Announces-Updated-Clinical-Data-Presentation-for-Lead-Candidate-DPX-Survivac-s-Phase-1b-2-Immunotherapy-Combination-Trial-at-the-ESMO-Immuno-Oncology-Congress-2018.html?f=22&fvtc=4&fvtv=34385IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 20182018-12-10T12:05:00Z<![CDATA[IMV to host an investor call on Thursday, December 13 at 8:30 a.m. ET to discuss the presentation IMV to host an investor call on Thursday, December 13 at 8:30 a.m. ET to discuss the presentation]]>https://www.globenewswire.com/news-release/2018/12/05/1662316/0/en/IMV-Welcomes-Marc-Jasmin-as-Senior-Director-Investor-Relations-and-Communications.html?f=22&fvtc=4&fvtv=34385IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications2018-12-05T12:05:00Z<![CDATA[DARTMOUTH, Nova Scotia, Dec. 05, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Marc Jasmin has joined the Company in the newly created role of Senior Director, Investor Relations and Communications.]]>